Sing Yeung Mak

Title: Sing Yeung Mak: Innovator in Pharmaceutical Compounds

Introduction

Sing Yeung Mak is a notable inventor based in Singapore, SG. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the human body. With a total of 2 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, one invention focuses on novel NADPH oxidase II inhibitors. This invention relates to their use in treating diseases mediated by NADPH oxidase enzymes. Another significant patent involves a piperazine derivative that has an affinity for the histamine H3 receptor. This compound, specifically 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine, and its pharmaceutically acceptable salts, are aimed at treating neurological or psychiatric diseases, including cognitive impairment and sleep disorders.

Career Highlights

Throughout his career, Sing Yeung Mak has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Glaxo Group Limited and GlaxoSmithKline Intellectual Property (No. 2) Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Sing Yeung Mak has collaborated with several professionals in his field, including Desmond John Best and Barry S. Orlek. These collaborations have likely enhanced his research and development efforts, leading to impactful inventions.

Conclusion

Sing Yeung Mak is a distinguished inventor whose work in pharmaceutical compounds demonstrates his commitment to advancing medical science. His patents reflect innovative approaches to treating complex diseases, showcasing the importance of research and collaboration in the field.